dataset
posted on 2025-11-03, 08:27 authored by Paolo Marzano, Cristiana Soldani, Valentina Cazzetta, Barbara Franceschini, Sara Terzoli, Anna Carletti, Michela Anna Polidoro, Federica Marchesi, Massimo Locati, Gianluca Basso, Ana Lleo, Guido Costa, Guido Torzilli, Flavio Milana, Rocco Piazza, Paola Spaggiari, Luca Di Tommaso, Joanna Mikulak, Domenico Mavilio, Matteo Donadon <p>Supplementary Table 3. List of significant genes (FDR-adjusted p-value < 0.05, and |Log2-FoldChange| > 0.25, detected in not less than 10% of cells) identified from the comparison Liver vs Colon within the inflammatory or immunoregulatory TAMs. In green are indicated the genes up-regulated in the liver, while in orange are indicated the colon-associated ones. Table related to Fig. 5A.</p>
Funding
Ministero della Salute (Italy Ministry of Health)
History
ARTICLE ABSTRACT
Early synchronous colorectal liver metastasis (CRLM) represents a clinical condition characterized by the simultaneous presence of primary colorectal cancer and metastatic liver lesions. In this study, we characterized the tissue-specific transcriptomes, phenotypes, and functional relevance of tumor-associated macrophages (TAM) within the tumor microenvironment (TME) of colorectal cancer and CRLM specimens from patients who underwent simultaneous surgical removal of these malignancies. The high-throughput single-cell transcriptional analysis revealed an inverse ratio of inflammatory and immunoregulatory TAMs in the colorectal cancer and CRLM TMEs, along with heterogeneity in both tumoral tissues. Furthermore, we found that inflammatory TAMs in colorectal cancer expressed inhibitory ligands that might support immune escape, thus favoring liver metastatic progression. In contrast, CRLM lesions possessed a highly immunosuppressive milieu characterized by large proliferative CTLA4+ immunoregulatory TAMs and the presence of IL7R+ cytotoxic TAMs. Higher frequencies of these specific TAM subsets in CRLM were associated with shorter disease-free survival and worse patient prognosis. The identification and characterization of immunoregulatory TAMs preferentially enriched in CRLM is key for the development of novel immunotherapeutic strategies aimed at boosting anticancer immune responses within the TME.
